The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, ...

The U.S. Food and Drug Administration has approved GSK's prefilled syringe presentation of Shingrix (zoster vaccine ...

The newly approved prefilled syringe version of Shingrix is expected to simplify administration and supports efforts to ...

GSK (GSK) stock in focus as the U.S. FDA approves a new prefilled syringe presentation of its shingles vaccine, Shingrix.

This image provided by GlaxoSmithKline shows the company's Shingrix vaccine. On Oct. 20, 2017, the Food and Drug Administration approved the vaccine to prevent painful shingles in people aged 50 ...

Lasting protection against shingles for adults over 50 with GSK's RZV vaccine. New data from ZOSTER-049 trial reveals over a decade of high efficacy. Plus, GSK's oral antibiotic, gepotidacin ...

GlaxoSmithKline's experimental vaccine to prevent the intensely painful condition known as shingles remained 90 percent effective in people over age 70 even four years after receiving the ...

GlaxoSmithKline agent Hz/su (aka GSK 1437173A), a Herpes zoster (shingles) vaccine candidate, met its primary endpoint in a Phase-III trial, the firm said, and is shaping up to be a potential ...

China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles vaccine in China, the UK drugmaker said on Thursday, lower than previously ...

Wednesday, GSK Plc (NYSE:GSK) reported second-quarter sales of $9.95 billion (7.88 billion Sterling Pounds), up 10% year-over-year and 13% on constant currency. The analysts estimated sales of $9. ...

GSK GSK0.28%increase; green up pointing triangle expects to further grow sales and earnings after its best-selling shingles vaccine Shingrix and the launch of RSV vaccine Arexvy helped the pharma ...

The US Food and Drug Administration (FDA) has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a ...